F
Francesca Pregnolato
Researcher at University of Milan
Publications - 62
Citations - 1480
Francesca Pregnolato is an academic researcher from University of Milan. The author has contributed to research in topics: Antiphospholipid syndrome & Medicine. The author has an hindex of 19, co-authored 53 publications receiving 1107 citations.
Papers
More filters
Journal ArticleDOI
Anti-Phospholipid Antibodies in COVID-19 Are Different From Those Detectable in the Anti-Phospholipid Syndrome.
Maria Orietta Borghi,Asmaa Beltagy,Emirena Garrafa,Daniele Curreli,Germana Cecchini,Caterina Bodio,Claudia Grossi,Simonetta Blengino,Angela Tincani,Franco Franceschini,Laura Andreoli,Maria Grazia Lazzaroni,Silvia Piantoni,Stefania Masneri,Francesca Crisafulli,Duilio Brugnoni,Maria Lorenza Muiesan,Massimo Salvetti,Gianfranco Parati,Erminio Torresani,Michael Mahler,Francesca Heilbron,Francesca Pregnolato,Martino F. Pengo,Francesco Tedesco,Nicola Pozzi,Pier Luigi Meroni +26 more
TL;DR: APL in COVID-19 patients are mainly directed against β2GPI but display an epitope specificity different from antibodies in antiphospholipid syndrome, which shows a low prevalence and is not associated with major thrombotic events.
Journal ArticleDOI
A non–complement-fixing antibody to β2 glycoprotein I as a novel therapy for antiphospholipid syndrome
Chiara Agostinis,Paolo Durigutto,Daniele Sblattero,Maria Orietta Borghi,Claudia Grossi,Filomena Guida,Roberta Bulla,Paolo Macor,Francesca Pregnolato,Pier Luigi Meroni,Francesco Tedesco +10 more
TL;DR: The CH2-deleted antibody represents an innovative approach potentially useful to treat APS patients refractory to standard therapy and a critical role for complement was supported by the inability of theCH2- deleted scFv-Fc to cause vessel occlusion and pregnancy failure.
Journal ArticleDOI
Clinical characterization of antiphospholipid syndrome by detection of IgG antibodies against β2 -glycoprotein i domain 1 and domain 4/5: ratio of anti-domain 1 to anti-domain 4/5 as a useful new biomarker for antiphospholipid syndrome.
Laura Andreoli,Cecilia Beatrice Chighizola,Cecilia Nalli,Maria Gerosa,M. Orietta Borghi,Francesca Pregnolato,Claudia Grossi,Alessandra Zanola,F. Allegri,Gary L. Norman,Michael Mahler,Pier Luigi Meroni,Angela Tincani +12 more
TL;DR: Evaluated the clinical relevance of domain specificity profiling of anti‐β2GPI IgG antibodies in antiphospholipid syndrome patients and in control groups of patients with systemic autoimmune rheumatic diseases and in asymptomatic antiph phospholipID antibody (aPL) carriers.
Journal ArticleDOI
Measuring IgA Anti-β2-Glycoprotein I and IgG/IgA Anti-Domain I Antibodies Adds Value to Current Serological Assays for the Antiphospholipid Syndrome
Charis Pericleous,Isabel Ferreira,Orietta Borghi,Francesca Pregnolato,Thomas McDonnell,Acely Garza-Garcia,Paul C. Driscoll,Silvia S. Pierangeli,David A. Isenberg,Yiannis Ioannou,Yiannis Ioannou,Ian Giles,Pier Luigi Meroni,Anisur Rahman +13 more
TL;DR: Measuring IgG aDI and IgA aβ2GPI and aDI may be useful in the management of patients with APS, particularly thrombotic APS.
Journal ArticleDOI
Clinical usefulness of autoantibodies to M-type phospholipase A2 receptor (PLA2R) for monitoring disease activity in idiopathic membranous nephropathy (IMN)
Antonella Radice,Barbara Trezzi,Umberto Maggiore,Francesca Pregnolato,Tiziana Stellato,Pietro Napodano,Davide Rolla,Gianpaola Pesce,Marco D'Amico,Domenico Santoro,Francesco Londrino,Federica Ravera,Giuseppe Ortisi,Renato Alberto Sinico +13 more
TL;DR: The data suggest that the serial evaluation of anti-PLA2R antibodies could help in optimal timing and duration of the immunosuppressive therapy, reducing over(under)-treatment and associated side-effects.